Search Results - "Ishkanian, Adrian S"

Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study by Lalonde, Emilie, MSc, Ishkanian, Adrian S, MD, Sykes, Jenna, MMath, Fraser, Michael, PhD, Ross-Adams, Helen, PhD, Erho, Nicholas, MSc, Dunning, Mark J, PhD, Halim, Silvia, MSc, Lamb, Alastair D, FRCS, Moon, Nathalie C, MMath, Zafarana, Gaetano, PhD, Warren, Anne Y, FRCPath, Meng, Xianyue, MSc, Thoms, John, MD, Grzadkowski, Michal R, BMath, Berlin, Alejandro, MD, Have, Cherry L, BSc, Ramnarine, Varune R, BCS, Yao, Cindy Q, MSc, Malloff, Chad A, MSc, Lam, Lucia L, BSc, Xie, Honglei, MMath, Harding, Nicholas J, PhD, Mak, Denise Y F, PhD, Chu, Kenneth C, PhD, Chong, Lauren C, BCS, Sendorek, Dorota H, BSc, P'ng, Christine, BSc, Collins, Colin C, Prof, Squire, Jeremy A, Prof, Jurisica, Igor, Prof, Cooper, Colin, PhD, Eeles, Rosalind, Prof, Pintilie, Melania, MSc, Dal Pra, Alan, MD, Davicioni, Elai, PhD, Lam, Wan L, Prof, Milosevic, Michael, MD, Neal, David E, Prof, van der Kwast, Theodorus, Prof, Boutros, Paul C, Prof, Bristow, Robert G, Prof

“…Summary Background Clinical prognostic groupings for localised prostate cancers are imprecise, with 30–50% of patients recurring after image-guided…”
Get full text

Copy number alterations of c‐MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy by Zafarana, Gaetano, Ishkanian, Adrian S., Malloff, Chad A., Locke, Jennifer A., Sykes, Jenna, Thoms, John, Lam, Wan L., Squire, Jeremy A., Yoshimoto, Maisa, Ramnarine, Varune Rohan, Meng, Alice, Ahmed, Omar, Jurisca, Igor, Milosevic, Michael, Pintilie, Melania, van der Kwast, Theo, Bristow, Robert G.

“…Despite the use of PSA, Gleason score, and T‐category as prognosticators in intermediate‐risk prostate cancer, 20–40% of patients will fail local therapy. In…”
Get full text

High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer by Ishkanian, Adrian S., Mallof, Chad A., Ho, James, Meng, Alice, Albert, Monique, Syed, Amena, van der Kwast, Theodorus, Milosevic, Michael, Yoshimoto, Maisa, Squire, Jeremy A., Lam, Wan L., Bristow, Robert G.

“…Approximately one‐third of prostate cancer patients present with intermediate risk disease. Interestingly, while this risk group is clinically well defined, it…”
Get full text

A tiling resolution DNA microarray with complete coverage of the human genome by Lam, Wan L, Ishkanian, Adrian S, Malloff, Chad A, Watson, Spencer K, deLeeuw, Ronald J, Chi, Bryan, Coe, Bradley P, Snijders, Antoine, Albertson, Donna G, Pinkel, Daniel, Marra, Marco A, Ling, Victor, MacAulay, Calum

“…We constructed a tiling resolution array consisting of 32,433 overlapping BAC clones covering the entire human genome. This increases our ability to identify…”
Get full text

Methods for high throughput validation of amplified fragment pools of BAC DNA for constructing high resolution CGH arrays by Watson, Spencer K, deLeeuw, Ronald J, Ishkanian, Adrian S, Malloff, Chad A, Lam, Wan L

“…The recent development of array based comparative genomic hybridization (CGH) technology provides improved resolution for detection of genomic DNA copy number…”
Get full text

Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer by Ishkanian, Adrian S, Zafarana, Gaetano, Thoms, John, Bristow, Robert G

“…Prostate cancer is the most common male cancer and up to one fifth of diagnosed patients will die of their disease. Current prognostic variables including…”
Get more information

NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy by LOCKE, Jennifer A, ZAFARANA, Gaetano, SYKES, Jenna, ROHAN RAMNARINE, Varune, MENG, Alice, AHMED, Omer, JURISICA, Igor, DER KWAST, Theo Van, BRISTOW, Robert G, ISHKANIAN, Adrian S, MILOSEVIC, Michael, THOMS, John, HAVE, Cherry L, MALLOFF, Chad A, LAM, Wan L, SQUIRE, Jeremy A, PINTILIE, Melania

“…Despite the use of prostate specific antigen (PSA), Gleason-score, and T-category as prognostic factors, up to 40% of patients with intermediate-risk prostate…”
Get full text